OptimizeRx Corporation

NasdaqCM:OPRX Stock Report

Market Cap: US$90.4m

OptimizeRx Future Growth

Future criteria checks 1/6

OptimizeRx is forecast to grow earnings and revenue by 56.9% and 9.9% per annum respectively while EPS is expected to grow by 58.9% per annum.

Key information

56.9%

Earnings growth rate

58.9%

EPS growth rate

Healthcare Services earnings growth31.9%
Revenue growth rate9.9%
Future return on equityn/a
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24
Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16
OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

May 31
Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio

Oct 12

Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

Sep 23
Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx extends reach with Cooler Screens Partnership

Jul 26

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Jun 27

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Nov 16
The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

Aug 13
Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Jul 15
A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Jun 24
Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Earnings and Revenue Growth Forecasts

NasdaqCM:OPRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026108-6682
12/31/2025100-10568
12/31/202490-18448
9/30/202488-24-1-2N/A
6/30/202483-18-2-2N/A
3/31/202478-18-6-5N/A
12/31/202372-18-8-7N/A
9/30/202363-1402N/A
6/30/202362-1424N/A
3/31/202362-1466N/A
12/31/202262-111011N/A
9/30/202263-1067N/A
6/30/202264-733N/A
3/31/202264-333N/A
12/31/202161001N/A
9/30/2021571-1-1N/A
6/30/2021521-1-1N/A
3/31/202147-1-1-1N/A
12/31/202043-2-6-6N/A
9/30/202034-6-6-5N/A
6/30/202029-7-7-6N/A
3/31/202027-5-8-6N/A
12/31/201925-3-3-2N/A
9/30/201924-101N/A
6/30/201924123N/A
3/31/201922022N/A
12/31/201821011N/A
9/30/201819000N/A
6/30/201816-1N/A-2N/A
3/31/201814-1N/A-2N/A
12/31/201712-2N/A-1N/A
9/30/201710-2N/A-2N/A
6/30/20179-2N/A-1N/A
3/31/20178-2N/A0N/A
12/31/20168-2N/A0N/A
9/30/20167-2N/A0N/A
6/30/20168-1N/A0N/A
3/31/20167-1N/A0N/A
12/31/20157-1N/A1N/A
9/30/201570N/A1N/A
6/30/201570N/A0N/A
3/31/201570N/A0N/A
12/31/20147-1N/A0N/A
9/30/20146-1N/A1N/A
6/30/20146-1N/A1N/A
3/31/20145-1N/A1N/A
12/31/201350N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OPRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OPRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OPRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OPRX's revenue (9.9% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: OPRX's revenue (9.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if OPRX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 04:52
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OptimizeRx Corporation is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserB. Riley Securities, Inc.
Constantine DavidesJMP Securities
Eric MartinuzziLake Street Capital Markets, LLC